Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Related Articles
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification
Anumana Demonstrates Global Readiness with Receipt of ISO 13485 CertificationCAMBRIDGE, Mass. – May 21, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today…May 21, 2024
Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
IT Business Net: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT)…July 06, 2022
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…May 23, 2022
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular diseaseJuly 12, 2022